Development of monoclonal antibodies to highly pathogenic avian influenza H5N1 virus and their application to diagnostics, prophylaxis, and therapy
| Autor: | Klimova Rr, Bondarev Vp, Loginova Sy, Deryabin Pg, Fediakina It, E V Chichev, L'vov Dk, O. V. Masalova, Borisevich Sv, Alla A. Kushch |
|---|---|
| Předmět: |
Rimantadine
medicine.drug_class Swine animal diseases Immunoblotting Hemagglutinin (influenza) Enzyme-Linked Immunosorbent Assay Hemagglutinin Glycoproteins Influenza Virus Chick Embryo medicine.disease_cause Monoclonal antibody Immunofluorescence Antibodies Viral Neutralization Birds Epitopes Mice Antigen Orthomyxoviridae Infections Virology medicine Animals Antigens Viral Mice Inbred BALB C biology medicine.diagnostic_test Influenza A Virus H5N1 Subtype virus diseases Antibodies Monoclonal General Medicine Antibiotic Prophylaxis Hemagglutination Inhibition Tests Influenza A virus subtype H5N1 Nucleoprotein Infectious Diseases Influenza A virus Influenza in Birds biology.protein medicine.drug |
| Zdroj: | Europe PubMed Central |
| Popis: | A panel of 17 monoclonal antibodies (MAbs) against highly pathogenic avian influenza virus (HPAIV) A/Duck/Novosibirsk/56/05 A/H5N1 (subclade 2.2) isolated in Russian Federation was developed. Immunoblot analysis showed that 12 MAbs were specific for the hemagglutinin (HA) and 5 MAbs for nucleoprotein (NP). All anti-HA MAbs were reactive in ELISA and immunofluorescence (IF) test and 10 of them were reactive in hemagglutination-inhibition (HI) and neutralization tests. Quantitative competitive ELISA revealed that anti-HA MAbs recognized at least 4 non-overlapping antigenic determinants and anti-NP MAbs recognized at least 3 non-overlapping antigenic determinants. Four sandwich ELISA procedures were developed using the obtained MAbs. These procedures are useful for 1) identification of avian, human, and swine influenza A viruses, 2) differentiation of avian influenza virus (AIV) from human and swine influenza viruses, 3) differentiation of AIV H5 from other AIV subtypes, and 4) differentiation between 2.2 and 2.3.2 subclades of H5N1 influenza viruses. Prophylactic and therapeutic efficacy of anti-HA MAbs with high neutralization activity was tested in BALB/c mice. A complete protection was achieved by single injection of MAbs (20 mg/kg) 24 hrs before challenge with 10 LD50 of HPAIV H5N1. Therapeutic efficacy was 90% that was similar to those of Rimantadine and Tamiflu. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|